Abstract:
Over the past decades many genetic variants have been identified that alter individuals’ responses to their medication resulting in ineffective treatment or adverse drug reactions. In England, through the NHS Network of Excellence in Pharmacogenomics, we have developed an implementation science program to adopt pharmacogenomics into routine clinical use. This has focused on the type of genetic test, the way that the data is transferred into an actionable format for the clinician, and determining the clinical outcomes of this intervention.
In this talk, I will discuss the clinical contexts of pharmacogenomics and how a new way of presenting genomic data is required for adoption at scale that is acceptable to both patients and health professionals. I will explore the use of point of care genetic testing and the potential for pre-emptive testing to improve medicines optimisation.
Biography:
Bill is a clinician scientist. Professor of Translational Genomic medicine at the University of Manchester and a Consultant in Clinical Genetics at the Manchester Centre for Genomic Medicine. He has a multidisciplinary research program in the implementation of pharmacogenomics in clinical practice and is the lead of the NHS England Network of Excellence in Pharmacogenomics and Medicines Optimisation. He is the immediate past President of the European Society of Human Genetics.
Join Zoom Meeting:
Link: https://cam-ac-uk.zoom.us/j/81376116442?pwd=hUOuGBqTbSG0GQcPH1N8k6vWL7nFGB.1
Meeting ID: 813 7611 6442
Passcode: 141113
